Lyell Immunopharma (LYEL) Return on Sales (2020 - 2026)
Lyell Immunopharma (LYEL) posted Return on Sales of 516.08% for Q1 2026, down 114.0% sequentially from 241.16% in Q4 2025, and down 33196.0% YoY from N/an in Q1 2025.
Lyell Immunopharma (LYEL) Return on Sales (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Return on Sales for 7 years, with the latest figure at 516.08% in Q1 2026.
- Quarterly Return on Sales fell 33196.0% year-over-year to 516.08% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 150.18% (down 497.0% YoY) and the FY2025 annual result came in at 79.6%, up 3808.0% from the prior year.
- Return on Sales retreated to 516.08% in Q1 2026 per LYEL's latest filing, from 241.16% in the prior quarter.
- Over five years, Return on Sales peaked at 0.0% in Q4 2022 and troughed at 627.93% in Q3 2022.
- A 5-year average of 175.96% and a median of 99.6% in 2024 frame the typical range for Return on Sales.
- The sharpest annual moves came in 2022 and 2023: Return on Sales tumbled 62771 bps in 2022, then surged 59991 bps in 2023.
- Over 5 years, Return on Sales stood at 0.0% in 2022, then sank by 8423430 bps to 236.03% in 2023, then plunged by 116 bps to 510.05% in 2024, then surged by 53 bps to 241.16% in 2025, then tumbled by 114 bps to 516.08% in 2026.
- According to Business Quant data, Return on Sales over the past three periods registered 516.08%, 241.16%, and 68.11% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 0.00% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -257.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -257.35% |
| Mar 31, 2026 | -516.08% |
| Dec 31, 2025 | -241.16% |
| Sep 30, 2025 | -68.11% |
| Jun 30, 2025 | -144.33% |
| Mar 31, 2025 | -184.12% |
| Dec 31, 2024 | -510.05% |
| Sep 30, 2024 | -36.59% |
| Jun 30, 2024 | -99.60% |
| Mar 31, 2024 | -249.70% |
| Dec 31, 2023 | -236.03% |
| Sep 30, 2023 | -28.02% |
| Jun 30, 2023 | -33.63% |
| Mar 31, 2023 | -12.82% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | -627.93% |
| Jun 30, 2022 | -0.04% |
| Mar 31, 2022 | -3.17% |
| Dec 31, 2021 | -0.62% |
| Sep 30, 2021 | -0.22% |